Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
22 mars 2023 17h09 HE
|
Senti Biosciences, Inc.
- SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - -...
Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting
14 mars 2023 16h35 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Premiere Synthetic Biology Event on Track for Record Attendance - 2023
01 févr. 2023 14h36 HE
|
SynBioBeta
SynBioBeta Global Synthetic Biology Conference Registration Open SynBioBeta announces event dates, keynotes, sponsors, and location SAN FRANCISCO, Feb. 01, 2023 (GLOBE NEWSWIRE) --...